TELA Bio to Report Fourth Quarter and Full Year 2020 Financial Results on March 24, 2021

TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the company will report fourth quarter and full year 2020 financial results on March 24, 2021. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.  

Conference Call and Webcast DetailsThe conference call can be accessed by dialing [phone] for participants in the U.S. or Canada and [phone] for international callers, using conference ID 8550518. A live and archived webcast of the event can be accessed via the Events & Presentations page of the investor section of TELA's website.

About TELA Bio, Inc.TELA Bio Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is committed to providing patients with advanced, economically effective biologic material repair solutions to patients to minimize long-term exposure to permanent synthetic materials and improve clinical outcomes. TELA Bio’s OviTex® and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. For more information, visit www.telabio.com.

Investor ContactGreg Chodaczek347-620-7010 [e-mail]